{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:18:31Z","timestamp":1777393111009,"version":"3.51.4"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.jocn.2011.10.008","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T12:31:54Z","timestamp":1335184314000},"page":"1016-1021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma"],"prefix":"10.1016","volume":"19","author":[{"given":"Omar N.","family":"Syed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher E.","family":"Mandigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan D.","family":"Killory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Canoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey N.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2011.10.008_b0005","first-page":"778","article-title":"Glioma immunology and immunotherapy","volume":"46","author":"Parney","year":"2000","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2011.10.008_b0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1006091608586","article-title":"Brain tumor survival: results from the National Cancer Data Base","volume":"40","author":"Surawicz","year":"1998","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0015","first-page":"8487","article-title":"Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model","volume":"63","author":"Prins","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocn.2011.10.008_b0020","first-page":"2143","article-title":"Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas","volume":"150","author":"Chi","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jocn.2011.10.008_b0025","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nrc1167","article-title":"Adoptive-cell-transfer therapy for the treatment of patients with cancer","volume":"3","author":"Dudley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jocn.2011.10.008_b0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jocn.2011.10.008_b0035","first-page":"1","article-title":"The cancer\/testis genes: review, standardization, and commentary","volume":"4","author":"Scanlan","year":"2004","journal-title":"Cancer Immun"},{"key":"10.1016\/j.jocn.2011.10.008_b0040","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.95.12.6919","article-title":"Identification of multiple cancer\/testis antigens by allogeneic antibody screening of a melanoma cell line library","volume":"95","author":"Chen","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2011.10.008_b0045","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1038\/sj.onc.1204552","article-title":"PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme","volume":"20","author":"Struss","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.jocn.2011.10.008_b0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.10170","article-title":"Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas","volume":"98","author":"Schmits","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jocn.2011.10.008_b0055","doi-asserted-by":"crossref","first-page":"11810","DOI":"10.1073\/pnas.92.25.11810","article-title":"Human neoplasms elicit multiple specific immune responses in the autologous host","volume":"92","author":"Sahin","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2011.10.008_b0060","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jcp.10215","article-title":"Cancer\/testis-associated genes: identification, expression profile, and putative function","volume":"194","author":"Zendman","year":"2003","journal-title":"J Cell Physiol"},{"issue":"Suppl. 2","key":"10.1016\/j.jocn.2011.10.008_b0065","first-page":"1","article-title":"Cancer vaccines 2003: opening address","volume":"3","author":"Old","year":"2003","journal-title":"Cancer Immun"},{"key":"10.1016\/j.jocn.2011.10.008_b0070","first-page":"61","article-title":"Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines","volume":"1653","author":"Mocellin","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jocn.2011.10.008_b0075","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4049\/jimmunol.168.2.951","article-title":"Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy","volume":"168","author":"Khong","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2011.10.008_b0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00002371-200307000-00002","article-title":"Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma","volume":"26","author":"Liu","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.jocn.2011.10.008_b0085","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/0008-5472.CAN-03-3505","article-title":"Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma","volume":"64","author":"Yu","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocn.2011.10.008_b0090","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1158\/0008-5472.CAN-03-3504","article-title":"HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells","volume":"64","author":"Liu","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocn.2011.10.008_b0095","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1038\/sj.onc.1208519","article-title":"Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy","volume":"24","author":"Liu","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jocn.2011.10.008_b0100","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14760584.5.6.793","article-title":"Glioma-specific antigens for immune tumor therapy","volume":"5","author":"Skog","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jocn.2011.10.008_b0105","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cncr.21669","article-title":"Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100","volume":"106","author":"Spaner","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2011.10.008_b0110","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2005.08.375","article-title":"Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells","volume":"23","author":"van Baren","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0115","first-page":"335","article-title":"Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers","volume":"5","author":"Scarcella","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2011.10.008_b0120","first-page":"7","article-title":"The frequent expression of cancer\/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma","volume":"4","author":"Ayyoub","year":"2004","journal-title":"Cancer Immun"},{"key":"10.1016\/j.jocn.2011.10.008_b0125","first-page":"3916","article-title":"Expression of cancer testis genes in human brain tumors","volume":"6","author":"Sahin","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2011.10.008_b0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3171\/PED\/2008\/1\/4\/305","article-title":"Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation","volume":"1","author":"Kasuga","year":"2008","journal-title":"J Neurosurg Pediatrics"},{"key":"10.1016\/j.jocn.2011.10.008_b0135","first-page":"7","article-title":"Cancer-testis (CT) antigen expression in medulloblastoma","volume":"8","author":"Oba-Shinjo","year":"2008","journal-title":"Cancer Immun"},{"key":"10.1016\/j.jocn.2011.10.008_b0140","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3340\/jkns.2008.43.4.190","article-title":"Expression of cancer-testis genes in brain tumors","volume":"43","author":"Lee","year":"2008","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.jocn.2011.10.008_b0145","first-page":"527","article-title":"The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas","volume":"54","author":"Rimoldi","year":"1993","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jocn.2011.10.008_b0150","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00401-007-0311-9","article-title":"Twenty-first century brain banking. Processing brains for research: the Columbia University methods","volume":"115","author":"Vonsattel","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jocn.2011.10.008_b0155","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","article-title":"A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening","volume":"94","author":"Chen","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2011.10.008_b0160","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1","article-title":"LAGE-1, a new gene with tumor specificity","volume":"76","author":"Lethe","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jocn.2011.10.008_b0165","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.jocn.2011.10.008_b0170","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1084\/jem.179.3.921","article-title":"Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes","volume":"179","author":"Gaugler","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.jocn.2011.10.008_b0175","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0215(19990909)82:6<901::AID-IJC21>3.0.CO;2-X","article-title":"CDNA and protein characterization of human MAGE-10","volume":"82","author":"Rimoldi","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jocn.2011.10.008_b0180","first-page":"4766","article-title":"The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40","volume":"56","author":"Tureci","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocn.2011.10.008_b0185","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/(SICI)1097-0215(20000301)85:5<726::AID-IJC21>3.0.CO;2-F","article-title":"CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis","volume":"85","author":"Gure","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jocn.2011.10.008_b0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(95)80053-0","article-title":"BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes","volume":"2","author":"Boel","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.jocn.2011.10.008_b0195","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1073\/pnas.95.9.5211","article-title":"Identification of a meiosis-specific protein as a member of the class of cancer\/testis antigens","volume":"95","author":"Tureci","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2011.10.008_b0200","doi-asserted-by":"crossref","first-page":"890","DOI":"10.4049\/jimmunol.160.2.890","article-title":"Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33","volume":"160","author":"Wang","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2011.10.008_b0205","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1084\/jem.184.6.2207","article-title":"Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes","volume":"184","author":"Wang","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.jocn.2011.10.008_b0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.180.1.35","article-title":"A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas","volume":"180","author":"Coulie","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.jocn.2011.10.008_b0215","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1073\/pnas.91.9.3515","article-title":"Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor","volume":"91","author":"Kawakami","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2011.10.008_b0220","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1073\/pnas.91.14.6458","article-title":"Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection","volume":"91","author":"Kawakami","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2011.10.008_b0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11060-006-9220-3","article-title":"Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy","volume":"81","author":"Saikali","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-009-0016-0","article-title":"Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper","volume":"97","author":"Driggers","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0235","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-06-1576","article-title":"Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics","volume":"13","author":"Zhang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2011.10.008_b0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11060-008-9534-4","article-title":"Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy","volume":"88","author":"Zhang","year":"2008","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/neuonc\/nop007","article-title":"A multigene predictor of outcome in glioblastoma","volume":"12","author":"Colman","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0250","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/01.jnen.0000186940.14779.90","article-title":"Histology-based expression profiling yields novel prognostic markers in human glioblastoma","volume":"64","author":"Dong","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jocn.2011.10.008_b0255","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/NEN.0b013e3181ba3952","article-title":"Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome","volume":"68","author":"Gabeau-Lacet","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jocn.2011.10.008_b0260","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1474-4422(10)70105-8","article-title":"Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers","volume":"9","author":"Jansen","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2011.10.008_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/nen.0b013e31815f65fb","article-title":"Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers","volume":"67","author":"Yip","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.jocn.2011.10.008_b0270","first-page":"1","article-title":"Cancer vaccines: an overview","volume":"8","author":"Old","year":"2008","journal-title":"Cancer Immun"},{"key":"10.1016\/j.jocn.2011.10.008_b0275","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1073\/pnas.161260098","article-title":"A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3","volume":"98","author":"Coulie","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2011.10.008_b0280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S","article-title":"Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1","volume":"80","author":"Marchand","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jocn.2011.10.008_b0285","doi-asserted-by":"crossref","first-page":"12198","DOI":"10.1073\/pnas.220413497","article-title":"Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers","volume":"97","author":"Jager","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2011.10.008_b0290","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1479-5876-8-100","article-title":"Cellular and vaccine therapeutic approaches for gliomas","volume":"8","author":"Hickey","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.jocn.2011.10.008_b0295","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1046\/j.1365-2567.2002.01507.x","article-title":"All in the head: obstacles for immune rejection of brain tumours","volume":"107","author":"Walker","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.jocn.2011.10.008_b0300","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0165-0173(03)00141-3","article-title":"T-cell immune responses in the brain and their relevance for cerebral malignancies","volume":"42","author":"Walker","year":"2003","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.jocn.2011.10.008_b0305","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1227\/01.NEU.0000068865.34216.3A","article-title":"Immunology and immunotherapy in neurosurgical disease","volume":"53","author":"Prins","year":"2003","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2011.10.008_b0310","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1586\/14737175.6.10.1481","article-title":"Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications","volume":"6","author":"Yang","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jocn.2011.10.008_b0315","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1593\/neo.05277","article-title":"EphA2 as a glioma-associated antigen: a novel target for glioma vaccines","volume":"7","author":"Hatano","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.jocn.2011.10.008_b0320","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11060-008-9566-9","article-title":"Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas","volume":"88","author":"Okada","year":"2008","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0325","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1479-5876-5-68","article-title":"Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma","volume":"5","author":"Ueda","year":"2007","journal-title":"J Transl Med"},{"key":"10.1016\/j.jocn.2011.10.008_b0330","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/14712598.4.10.1609","article-title":"Cytokine gene therapy for malignant glioma","volume":"4","author":"Okada","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jocn.2011.10.008_b0335","first-page":"8","article-title":"A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies","volume":"10","author":"Liggins","year":"2010","journal-title":"Cancer Immun"},{"key":"10.1016\/j.jocn.2011.10.008_b0340","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-0095-03","article-title":"Gp100(209\u20132M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells","volume":"10","author":"Walker","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2011.10.008_b0345","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1200\/JCO.2008.17.3161","article-title":"Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens","volume":"26","author":"Slingluff","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0350","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1158\/1078-0432.CCR-08-0022","article-title":"Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization","volume":"14","author":"Walker","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2011.10.008_b0355","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1200\/JCO.2007.13.3165","article-title":"Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma","volume":"26","author":"Sosman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-008-9734-y","article-title":"Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas","volume":"92","author":"Sioka","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2011.10.008_b0365","first-page":"2","article-title":"HAGE, a cancer\/testis antigen expressed at the protein level in a variety of cancers","volume":"10","author":"Mathieu","year":"2010","journal-title":"Cancer Immun"},{"key":"10.1016\/j.jocn.2011.10.008_b0370","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.semcancer.2003.09.007","article-title":"Peptide vaccine trials for melanoma: preclinical background and clinical results","volume":"13","author":"Talebi","year":"2003","journal-title":"Semin Cancer Biol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586811006631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586811006631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:15:04Z","timestamp":1760822104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586811006631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0967586811006631"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2011.10.008","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2011.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}